New BIOSECURE Act Targets Foreign-Linked Biotech

Signaling a major shift in U.S. policy on biotechnology supply chain security, Congress has enacted the BIOSECURE Act as part of the Fiscal Year 2026 National Defense Authorization Act (NDAA), The Act imposes broad restrictions on federal contracting and funding involving certain foreign-linked biotechnology companies, with significant implications for pharmaceutical, biotech, and life sciences organizations….
By: Fox Rothschild LLP